OncoMatch/Clinical Trials/NCT06214572
Radiation Therapy in Unresectable Gall Bladder Cancer
Is NCT06214572 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Systemic therapy (Gemcitabine plus Cisplatin) and Systemic therapy (Gemcitabine plus oxaliplatin) for gall bladder cancer.
Treatment: Systemic therapy (Gemcitabine plus Cisplatin) · Systemic therapy (Gemcitabine plus oxaliplatin) · Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab) · Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel) — The goal of this clinical trial is to compare two treatment regimes, namely, systemic therapy (chemotherapy and/or immunotherapy) alone vs. systemic therapy and radiation therapy in patients with inoperable but localized gallbladder cancer. The main questions it aims to answer are: * Whether adding radiation therapy to systemic therapy improves overall survival? * What are the effects on other endpoints like cancer-free intervals, side effects, and quality of life? Participants will be randomly assigned to one of the two treatment regimes mentioned earlier by a computer-based program. Researchers will compare survival and quality of life outcomes between the two groups.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: gemcitabine-based chemotherapy — initial
Cannot have received: abdominal therapeutic radiation
Lab requirements
Blood counts
Hb > 80 g/L, ANC ≥ 1.5 x 10^9/L, platelets ≥ 100 x 10^9/L
Kidney function
Creatinine ≤ 1.5 ULN, Creatinine clearance >= 50 mL/min
Liver function
bilirubin ≤ 2 x upper limit normal (ULN), AST/ALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN), S. albumin ≥ 30 g/L
Normal hematological and renal and hepatic functions allowing safe delivery of chemotherapy Hematological- Hb> 80 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L. Liver functions- bilirubin ≤ 2 x upper limit normal (ULN), AST/ALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN) S. albumin ≥ 30 g/L Renal function- Creatinine ≤ 1.5 ULN, Creatinine clearance >= 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06214572 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abdominal therapeutic radiation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages